Stryker said it closed the buyout of SBi’s North American assets and expects to close on its French and German assets once regulatory authorities there OK the deal.
Stryker agreed in June to pay roughly $375 million for Morrisville, Pa.-based SBi’s total ankle replacement system, plus finger, wrist and elbow products. The net cost to Stryker is slated to be roughly $285 million "after taking into account the present value of the tax benefits as a result of the asset purchase structure," the company said at the time.
SBi’s Scandinavian Total Ankle Replacement system is the only FDA-approved, cementless, 3-piece total ankle replacement device.
Stryker has said the acquisition is expected to dilute its adjusted earnings per share by about 2¢ this year.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.